Incyte (INCY) Misses Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Incyte Reports 2018 Fourth Quarter and Year-End Financial Results, Provides 2019 Financial Guidance and Provides Updates on Key Clinical Programs
February 14, 2019 7:00 AM ESTTotal product-related revenues of $468 million (+25%) in 4Q 2018 and $1.7 billion (+25%) for the full year 2018 Jakafi® (ruxolitinib) revenues of $380 million (+26%) in 4Q 2018 and $1.4 billion (+22%) for the full year 2018 Multiple late-stage product candidates provide additional opportunities to further accelerate revenue growth
Conference Call and Webcast Scheduled Today at 8:00 a.m. EST
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte Corporation (Nasdaq: INCY) today reports 2018 fourth quarter and year-end financial results, announces 2019 guidance and provides a... More
